ES2095043T3 - Composicion para preparados orales. - Google Patents

Composicion para preparados orales.

Info

Publication number
ES2095043T3
ES2095043T3 ES93905625T ES93905625T ES2095043T3 ES 2095043 T3 ES2095043 T3 ES 2095043T3 ES 93905625 T ES93905625 T ES 93905625T ES 93905625 T ES93905625 T ES 93905625T ES 2095043 T3 ES2095043 T3 ES 2095043T3
Authority
ES
Spain
Prior art keywords
composition
oral preparations
basic
weight based
unpleasant flavor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93905625T
Other languages
English (en)
Inventor
Toshio Yajima
Kuniaki Ishii
Nobuo Umeki
Shigeru Itai
Hidefumi Hayashi
Kimihide Shimano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2095043T3 publication Critical patent/ES2095043T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

SE PRESENTA UNA COMPOSICION PARA PREPARACIONES ORALES QUE CONSTA DE UN COMPLEJO FORMADO MEDIANTE LA DISPERSION O LA DISOLUCION DE UN MEDICAMENTO BASICO DE SABOR DESAGRADABLE Y UN COMPUESTO DE POLIMERO DE FUNCION EN UNA SUSTANCIA QUE TIENE UN PUNTO DE FUSION BAJO, DEL 10 AL 70% EN PESO BASADO EN LA COMPOSICION DE ALCOHOL DE AZUCAR Y DE UN 0.1 A UN 7% EN PESO BASADO EN LA COMPOSICION DE UN OXIDO BASICO. LA COMPOSICION ES EXCELENTE PARA PREPARACIONES ORALES, PARA EL MASTICADO DE MEDICAMENTOS BASICOS DE SABOR DESAGRADABLE Y TIENE UN COMPORTAMIENTO EXCELENTE PARA USO BIOLOGICO.
ES93905625T 1992-03-12 1993-03-10 Composicion para preparados orales. Expired - Lifetime ES2095043T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5344292 1992-03-12
JP21990492 1992-08-19

Publications (1)

Publication Number Publication Date
ES2095043T3 true ES2095043T3 (es) 1997-02-01

Family

ID=26394153

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93905625T Expired - Lifetime ES2095043T3 (es) 1992-03-12 1993-03-10 Composicion para preparados orales.

Country Status (12)

Country Link
US (1) US5707646A (es)
EP (1) EP0630233B1 (es)
JP (1) JP3265680B2 (es)
AT (1) ATE143258T1 (es)
AU (1) AU670428B2 (es)
CA (1) CA2131547C (es)
DE (1) DE69305069T2 (es)
ES (1) ES2095043T3 (es)
FI (1) FI109657B (es)
MX (1) MXPA93001352A (es)
NO (1) NO308022B1 (es)
WO (1) WO1993017667A1 (es)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332801T2 (de) * 1992-11-30 2004-01-29 Kv Pharm Co Geschmacksmaskierte pharmazeutische substanzen
EP0744941B1 (en) * 1994-02-16 2003-06-04 Abbott Laboratories Process for preparing fine particle pharmaceutical formulations
US5728403A (en) * 1994-10-05 1998-03-17 The Board Of Regents Of The University Of Nebraska Coating technology for taste masking orally administered bitter drugs
DE29502547U1 (de) * 1995-02-16 1995-03-30 Roehm Gmbh Thermoplastisches Überzugs- und Bindemittel für Arzneiformen
DK0826376T3 (da) * 1995-05-02 2007-04-16 Taisho Pharmaceutical Co Ltd Sammensætning til oral indgivelse
AUPO637197A0 (en) * 1997-04-23 1997-05-15 F.H. Faulding & Co. Limited Taste-masked pharmaceutical compositions
DE19617487A1 (de) † 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
DE19706978A1 (de) * 1997-02-21 1998-08-27 Ulrich Dr Posanski Kombinationspräparat für oral applizierbare Antibiotika
DE19706979A1 (de) * 1997-02-21 1998-08-27 Lindopharm Gmbh Kombinationspräparat für oral applizierbare Erythromycine
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6861411B1 (en) * 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
KR100514330B1 (ko) * 1997-12-31 2006-02-17 주식회사 중외제약 난용성 약물을 함유하는 코팅정
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
JP3466921B2 (ja) * 1998-06-03 2003-11-17 大塚製薬株式会社 味マスキング医薬製剤
WO2000018372A1 (fr) * 1998-09-30 2000-04-06 Taisho Pharmaceutical Co., Ltd. Granules pour preparations orales
ES2306646T3 (es) * 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
KR100768034B1 (ko) * 1999-03-17 2007-10-17 다이이찌 세이야꾸 가부시기가이샤 의약 조성물
SI20244A (sl) * 1999-05-19 2000-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Granulacija v talini
IN191239B (es) 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
CZ20023167A3 (cs) * 2000-02-29 2003-10-15 Teva Pharmaceutical Industries Ltd. Způsob přípravy klaritromycinu a klaritromycinového meziproduktu, v podstatě prostého oximu a farmaceutický prostředek, který jej obsahuje
AU2001263812B2 (en) * 2000-03-28 2004-09-23 Sandoz Ag Granulated particles with masked taste
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
ATE361061T1 (de) 2000-04-20 2007-05-15 Novartis Ag Beschichtungszusammensetzung zur geschmacksmaskierung
AU2001275043A1 (en) 2000-05-31 2001-12-11 Drugtech Corporation Mineral supplement
WO2001091761A1 (fr) * 2000-06-01 2001-12-06 Taisho Pharmaceutical Co.,Ltd. Matrices pour preparations orales
AU7105501A (en) 2000-07-17 2002-01-30 Yamanouchi Pharma Co Ltd Pharmaceutical composition improved in peroral absorbability
US20040022848A1 (en) * 2000-09-19 2004-02-05 Hiroshi Kikuchi Medicinal composition
CA2424770A1 (en) 2000-10-06 2003-04-03 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation
WO2002038577A2 (en) * 2000-10-13 2002-05-16 Advancis Pharmaceuticals Extended release erythromycin derivatives
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
JP4706096B2 (ja) * 2000-10-23 2011-06-22 大正製薬株式会社 不快な味を呈する塩基性薬物配合製剤
AU2002224053A1 (en) * 2000-11-21 2002-06-03 Kyorin Pharmaceutical Co. Ltd. Dry syrup preparations
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AU2002327418A1 (en) * 2001-08-01 2003-02-17 Bristol-Myers Squibb Company Taste masking composition
EP1920766B1 (en) 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
RU2004123637A (ru) 2002-02-01 2005-04-20 Пфайзер Продактс Инк. (Us) Фармацевтические лекарственные формы контролируемого высвобождения ингибитора транспортного белка холестерилового
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
AU2003245504A1 (en) * 2002-06-14 2003-12-31 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
WO2004014342A1 (en) 2002-08-12 2004-02-19 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
JP2006513186A (ja) 2002-12-20 2006-04-20 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害剤およびｈｍｇ−ｃｏａレダクターゼ阻害剤を含む剤形
US20040146553A1 (en) * 2002-12-23 2004-07-29 Aventis Pharma S.A. Compositions for oral administration of active principles requiring masking of taste
KR100508992B1 (ko) * 2003-03-31 2005-08-17 한국유나이티드제약 주식회사 쓴 맛을 개선한 클래리스로마이신 경구용 약제 조성물 및 그의 제조 방법
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
US8313775B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
US8313776B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
JP2007502294A (ja) * 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
EP1658034A4 (en) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
JP2007513869A (ja) * 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2007511500A (ja) * 2003-11-14 2007-05-10 ファイザー・プロダクツ・インク 肥満治療のためのｍｔｐ阻害剤の固体非晶性分散体
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053655A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
WO2005053651A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005053656A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
CA2547773A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
RU2006119453A (ru) * 2003-12-04 2007-12-20 Пфайзер Продактс Инк. (Us) Получение посредством основанных на применении жидкостей способов лекарственные формы азитромицина с большим количеством частиц
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
JP2007513937A (ja) * 2003-12-09 2007-05-31 ファイザー インコーポレイテッド Ｈｉｖプロテアーゼ阻害剤を含む組成物
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
WO2005062898A2 (en) * 2003-12-24 2005-07-14 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
BRPI0510273A (pt) 2004-05-25 2007-10-30 Pfizer Prod Inc derivados de tetraazabenzo[e]azuleno e análogos destes
EP1757277A4 (en) * 2004-06-03 2012-11-21 Taisho Pharmaceutical Co Ltd ORAL PREPARATIONS AND METHOD FOR THEIR MANUFACTURE
JP2008505124A (ja) * 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
KR20100033419A (ko) * 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
WO2009085637A1 (en) * 2007-12-21 2009-07-09 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
BRPI0909469A2 (pt) * 2008-03-31 2015-12-29 Metabolex Inc compostos de oximetileno de arila e usos dos mesmos
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
DE102009019268A1 (de) * 2009-04-28 2010-11-11 Lts Lohmann Therapie-Systeme Ag Arzneimittel mit poröser Matrix
RU2012101214A (ru) 2009-06-16 2013-07-27 Пфайзер Инк. Лекарственные формы апиксабана
US8410127B2 (en) * 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
EP2571860A1 (en) 2010-05-21 2013-03-27 Pfizer Inc 2-phenyl benzoylamides
CN103037843A (zh) 2010-06-23 2013-04-10 麦它波莱克斯股份有限公司 5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
EA032356B1 (ru) 2014-03-17 2019-05-31 Пфайзер Инк. Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
EP3319595A4 (en) * 2015-06-30 2019-04-03 Kemin Industries, Inc. ENCAPSULATED ACTIVE INGREDIENTS FOR REGULATED ENERGETIC RELEASE
CA3032432A1 (en) 2016-08-03 2018-02-08 Charles A. Mcwherter Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CA3056030A1 (en) 2017-03-10 2018-09-13 Pfizer Inc. Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
US11254660B2 (en) 2018-08-31 2022-02-22 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
CA3136880C (en) 2019-04-19 2023-09-19 Pfizer Inc. Anti-proliferative agents for treating pah
EP3972596A1 (en) 2019-05-20 2022-03-30 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
US20220363673A1 (en) 2019-06-28 2022-11-17 Pfizer Inc. 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JPWO2021182467A1 (es) * 2020-03-11 2021-09-16
PE20231215A1 (es) 2020-06-09 2023-08-17 Pfizer Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos
TW202337429A (zh) 2021-12-01 2023-10-01 美商輝瑞股份有限公司 支鏈酮酸脫氫酶激酶（ｂｃｋｄｋ）抑制劑及／或降解劑
WO2023105387A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
WO2024075051A1 (en) 2022-10-07 2024-04-11 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
WO2024084390A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Compounds for the activation of ampk
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
WO2024084360A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000254A (en) * 1966-04-25 1976-12-28 Schmid Laboratories, Inc. Fungimycin compositions
US3627885A (en) * 1968-07-18 1971-12-14 Rit Rech Ind Therapeut Stabilized antibiotic compositions for animal feeding
US3857939A (en) * 1971-08-18 1974-12-31 Hoffmann La Roche Chewable sodium-free vitamin c tablets
US3865935A (en) * 1972-08-10 1975-02-11 Abbott Lab Tableting of erythromycin base
US4340582A (en) * 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
SE8203953D0 (sv) * 1982-06-24 1982-06-24 Astra Laekemedel Ab Pharmaceutical mixture
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US5271946A (en) * 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
US4925675A (en) * 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
WO1990012566A1 (fr) * 1989-04-18 1990-11-01 Taisho Pharmaceutical Co., Ltd. Procede pour fabriquer une preparation orale aromatique
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
DE69332801T2 (de) * 1992-11-30 2004-01-29 Kv Pharm Co Geschmacksmaskierte pharmazeutische substanzen

Also Published As

Publication number Publication date
NO308022B1 (no) 2000-07-10
FI944165A (fi) 1994-09-09
ATE143258T1 (de) 1996-10-15
CA2131547C (en) 2002-02-12
WO1993017667A1 (en) 1993-09-16
DE69305069T2 (de) 1997-03-13
NO943341L (no) 1994-09-09
AU3648493A (en) 1993-10-05
JPH06116138A (ja) 1994-04-26
DE69305069D1 (de) 1996-10-31
EP0630233B1 (en) 1996-09-25
EP0630233A1 (en) 1994-12-28
FI944165A0 (fi) 1994-09-09
FI109657B (fi) 2002-09-30
CA2131547A1 (en) 1993-09-16
JP3265680B2 (ja) 2002-03-11
MXPA93001352A (es) 2005-02-22
AU670428B2 (en) 1996-07-18
NO943341D0 (no) 1994-09-09
US5707646A (en) 1998-01-13

Similar Documents

Publication Publication Date Title
ES2095043T3 (es) Composicion para preparados orales.
DE3686483T2 (de) Arzneimittel.
ATE143830T1 (de) Mikrokapseln mit wänden aus primären alkoholfunktionen enthaltenden polysacchariden, und zusammensetzungen daraus
DE60108154D1 (de) Pharmazeutische Zubereitungen enthaltend Clavulansäure
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
AR009231A1 (es) Formulaciones en aerosol de formoterol.
AR224323A1 (es) Composicion insecticida sinergizada que contiene crisantemato de n-(3,4,5,6-terahidroftalimido)-metilo o de 2-ali-3-metil-ciclopent-2-en-1-on-4-ilo y 3-fenoxibencil-2',2'-dimetil-3'-(2",2"-diclorovinil)-ciclopropanocarboxilato
DE69521693T2 (de) Taxanderivate enthaltende arzneizubereitungen
DK157689A (da) Farmaceutiske piroxicammidler i vandige oploesninger samt fremgangsmaade til fremstilling heraf
DE3583916D1 (de) Waessrige arzneiformulierungen des piroxicammonohydrats.
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
ES2058988T3 (es) Preparacion de medicamentos para el tratamiento sistemico de peces ornamentales y utiles.
ES2171459T3 (es) Polvo para administracion nasal de farmaco peptidico o proteinaceo.
DE69530380D1 (de) Retropeptide, antikörper dagegen und deren verwendungen in der impfung und in vitro diagnostik
ATE85213T1 (de) Einen wirkstoff und ein in wasser quellendes polymer enthaltendes arzneimittel.
ATE65395T1 (de) Acetylcystein enthaltendes, festes, wasserloeslisches arzneimittel.
DE60032372D1 (de) Arzneizubereitungen enthaltend paclitaxel eingeschlossen in nanopartikeln von polymerischen mizellen
DE59107240D1 (de) Emulgatorfreie Emulsionspolymere in pharmazeutischen Zubereitungen mit verzögerter Wirkstofffreigabe und ihre Herstellung
DE69211743D1 (de) Aureobasidin enthaltendes Arzneimittel
TH61593B (th) สารผสมที่มีเตตราไฮโดรลิพสตาติน
BE882841A (fr) Nouvelle substance biologiquement active, sa preparation et les medicaments qui la contiennent
ATE4713T1 (de) 2-oxo-benzothiazolin-, benzoxazolin- oder indolin-derivate, deren herstellung und derartige verbindungen enthaltende pharmazeutische zusammensetzungen.
BR9805026A (pt) Compostos contdndo tetrahidrolipstatina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 630233

Country of ref document: ES